Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALMS: Alirocumab in Sepsis
NCT05469347Phase 1Completed
- Sponsor
- Jonathan Sevransky
- Start
- Jan 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sepsis comparing Alirocumab with Placebo (2 arms). Primary endpoints: Bacterial endotoxin level and Lipoteichoic acid level. Started Jan 2023; status: completed.
02
Drugs
alirocumab
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05469347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469347.